"Pharmaceutical Network Market Analysis" Recently, The East Sunshine Drug's Aiomeprazole magnesium intestinal capsule, Zhejiang Bed Pharmaceutical's injection of Esomeprazole sodium has been approved by the State Drug Administration for production, so that proton pump inhibitors (PPI) again get market attention.
It is understood that peptic ulcer is a common digestive system disease, proton pump inhibitors are anti-peptic ulcers commonly used drugsAt present, the domestic approved proton pump inhibitors include Aiomeprazole, omeprazole, Lansolaazole, Rebellaazole, pinotrazazole, apraazole and other 6 kinds.
As proton pump inhibitors and related products in the domestic market has entered a mature period, and innovative drugs, in recent years, the market growth rate of anti-peptic ulcer drugs continued to slowAccording to Minet.com, sales of peptic ulcer drugs for the treatment of peptic ulcerdrugs in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals in 2019 were 39.966 billion yuan, up 1.01% year-on-year.
In 2019, sales of TOP10, a terminal therapeutic peptic ulcer drug product in China's public medical institutions, exceeded 1 billion yuanAmong them, injectable sodium pyroprazole topped the list with sales of 6.709 billion yuan, followed by injectable omeprazole with sales of 6.39 0 billion yuanIn addition, sales of sodium Aiomeprazole with injection, lansolarazole for injection, sodium rebella, sodium rebella, and rebellaazole were all sold at more than 2 billion yuan.
In addition, in terms of the treatment of peptic ulcer drug products TOP10 brands, Osecon and AstraZeno have two brands on the list, sales of more than 1 billion yuan of brands have sevenAmong them, Osekang's injection of omeprazole sodium with sales of 2.764 billion yuan ranked first, Zhengda Qing Pharmaceutical Group's injection of aiomeprazole sales led by 23.28 percent growth rate, Lizhu Group's heavy products Apraazole tablet sales performance is also excellent, reached nearly 1 billion yuan of sales.
It is worth mentioning that, with the promotion of the volume procurement policy, at present, Wuhan City, Fujian Province, Shandong Province, Jiangxi Province, Qinghai Province and many other regions will be PPI drugs into the volume procurement list.
For example, on May 26, Qinghai Provincial Medical Security Bureau issued a letter to centralize the purchase of 64 drugs, requiring municipal medical institutions to report the actual purchase quantity of 64 drugs in 2019 and the expected purchase quantity from July 1, 2020 to June 30, 2021Six proton pump inhibitors, such as Esomeprazole, Omeprazole, Lansolaazole, Rebellaazole, Pisoprazole, and Epraazole, are included in the list.
From Wuhan City, Fujian Province has announced the results of the volume of procurement, Wuhan City with volume procurement of 5 proton pump inhibitors have a number of enterprises winning the bid, of which Osaykang selected 3 varieties, AstraZeneca selected 2 varieties, Wutian, Luoxin Pharmaceuticals, Zhengda Tianqing Pharmaceutical Group also have products winning the bidThe results of drug band procurement in Fujian Province show that the winning bidder for proton pump inhibitors includes Hyscoe, Xinhua Pharmaceuticals and so on.
At present, Shandong, Jiangxi, Qinghai and other provincial drug tape procurement is still in progress, proton pump inhibitors and other drugs in the results of the election is worthy of attention As more local drug-belt procurement continues to advance, the industry is expected to expect that more areas will also include proton pump inhibitors in the collection list, conducive to further lower drug prices, good for patients.